Abstract
Since the introduction of propranolol (Inderal -ICI) two more β -adrenergic receptor blocking agents have become available for clinical use, practolol (Eraldin - ICI) and oxprenolol (Trasicor - Ciba). Both manufacturers claim that their product is less likely than propranolol to precipitate heart failure or asthma. All three drugs, although structurally similar, have different pharmacological properties which are summarised in the table. The use of the drugs in different clinical situations must therefore be considered separately.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
